Inhibition of Ebola virus entry by a C-peptide targeted to endosomes

Emily Happy Miller, Joseph S. Harrison, Sheli R. Radoshitzky, Chelsea D. Higgins, Xiaoli Chi, Lian Dong, Jens H. Kuhn, Sina Bavari, Jonathan R. Lai, Kartik Chandran

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Ebola virus (EboV) and Marburg virus (MarV) (filoviruses) are the causative agents of severe hemorrhagic fever. Infection begins with uptake of particles into cellular endosomes, where the viral envelope glycoprotein (GP) catalyzes fusion between the viral and host cell membranes. This fusion event is thought to involve conformational rearrangements of the transmembrane subunit (GP2) of the envelope spike that ultimately result in formation of a six-helix bundle by the N- and C-terminal heptad repeat (NHR and CHR, respectively) regions of GP2. Infection by other viruses employing similar viral entry mechanisms (such as HIV-1 and severe acute respiratory syndrome coronavirus) can be inhibited with synthetic peptides corresponding to the native CHR sequence ("C- peptides"). However, previously reported EboV C-peptides have shown weak or insignificant antiviral activity. To determine whether the activity of a C-peptide could be improved by increasing its intracellular concentration, we prepared an EboV C-peptide conjugated to the arginine-rich sequence from HIV-1 Tat, which is known to accumulate in endosomes. We found that this peptide specifically inhibited viral entry mediated by filovirus GP proteins and infection by authentic filoviruses. We determined that antiviral activity was dependent on both the Tat sequence and the native EboV CHR sequence. Mechanistic studies suggested that the peptide acts by blocking a membrane fusion intermediate.

Original languageEnglish (US)
Pages (from-to)15854-15861
Number of pages8
JournalJournal of Biological Chemistry
Volume286
Issue number18
DOIs
StatePublished - May 6 2011

Fingerprint

Ebolavirus
Virus Internalization
C-Peptide
Endosomes
Viruses
Peptides
Antiviral Agents
HIV-1
Glycoproteins
Fusion reactions
Marburgvirus
Severe Acute Respiratory Syndrome
Coronavirus
Membrane Fusion
Terminal Repeat Sequences
Virus Diseases
Infection
Arginine
Fever
Cell Membrane

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Miller, E. H., Harrison, J. S., Radoshitzky, S. R., Higgins, C. D., Chi, X., Dong, L., ... Chandran, K. (2011). Inhibition of Ebola virus entry by a C-peptide targeted to endosomes. Journal of Biological Chemistry, 286(18), 15854-15861. https://doi.org/10.1074/jbc.M110.207084

Inhibition of Ebola virus entry by a C-peptide targeted to endosomes. / Miller, Emily Happy; Harrison, Joseph S.; Radoshitzky, Sheli R.; Higgins, Chelsea D.; Chi, Xiaoli; Dong, Lian; Kuhn, Jens H.; Bavari, Sina; Lai, Jonathan R.; Chandran, Kartik.

In: Journal of Biological Chemistry, Vol. 286, No. 18, 06.05.2011, p. 15854-15861.

Research output: Contribution to journalArticle

Miller, EH, Harrison, JS, Radoshitzky, SR, Higgins, CD, Chi, X, Dong, L, Kuhn, JH, Bavari, S, Lai, JR & Chandran, K 2011, 'Inhibition of Ebola virus entry by a C-peptide targeted to endosomes', Journal of Biological Chemistry, vol. 286, no. 18, pp. 15854-15861. https://doi.org/10.1074/jbc.M110.207084
Miller EH, Harrison JS, Radoshitzky SR, Higgins CD, Chi X, Dong L et al. Inhibition of Ebola virus entry by a C-peptide targeted to endosomes. Journal of Biological Chemistry. 2011 May 6;286(18):15854-15861. https://doi.org/10.1074/jbc.M110.207084
Miller, Emily Happy ; Harrison, Joseph S. ; Radoshitzky, Sheli R. ; Higgins, Chelsea D. ; Chi, Xiaoli ; Dong, Lian ; Kuhn, Jens H. ; Bavari, Sina ; Lai, Jonathan R. ; Chandran, Kartik. / Inhibition of Ebola virus entry by a C-peptide targeted to endosomes. In: Journal of Biological Chemistry. 2011 ; Vol. 286, No. 18. pp. 15854-15861.
@article{3a2d1e281ef84060ae1656e355c4982c,
title = "Inhibition of Ebola virus entry by a C-peptide targeted to endosomes",
abstract = "Ebola virus (EboV) and Marburg virus (MarV) (filoviruses) are the causative agents of severe hemorrhagic fever. Infection begins with uptake of particles into cellular endosomes, where the viral envelope glycoprotein (GP) catalyzes fusion between the viral and host cell membranes. This fusion event is thought to involve conformational rearrangements of the transmembrane subunit (GP2) of the envelope spike that ultimately result in formation of a six-helix bundle by the N- and C-terminal heptad repeat (NHR and CHR, respectively) regions of GP2. Infection by other viruses employing similar viral entry mechanisms (such as HIV-1 and severe acute respiratory syndrome coronavirus) can be inhibited with synthetic peptides corresponding to the native CHR sequence ({"}C- peptides{"}). However, previously reported EboV C-peptides have shown weak or insignificant antiviral activity. To determine whether the activity of a C-peptide could be improved by increasing its intracellular concentration, we prepared an EboV C-peptide conjugated to the arginine-rich sequence from HIV-1 Tat, which is known to accumulate in endosomes. We found that this peptide specifically inhibited viral entry mediated by filovirus GP proteins and infection by authentic filoviruses. We determined that antiviral activity was dependent on both the Tat sequence and the native EboV CHR sequence. Mechanistic studies suggested that the peptide acts by blocking a membrane fusion intermediate.",
author = "Miller, {Emily Happy} and Harrison, {Joseph S.} and Radoshitzky, {Sheli R.} and Higgins, {Chelsea D.} and Xiaoli Chi and Lian Dong and Kuhn, {Jens H.} and Sina Bavari and Lai, {Jonathan R.} and Kartik Chandran",
year = "2011",
month = "5",
day = "6",
doi = "10.1074/jbc.M110.207084",
language = "English (US)",
volume = "286",
pages = "15854--15861",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "18",

}

TY - JOUR

T1 - Inhibition of Ebola virus entry by a C-peptide targeted to endosomes

AU - Miller, Emily Happy

AU - Harrison, Joseph S.

AU - Radoshitzky, Sheli R.

AU - Higgins, Chelsea D.

AU - Chi, Xiaoli

AU - Dong, Lian

AU - Kuhn, Jens H.

AU - Bavari, Sina

AU - Lai, Jonathan R.

AU - Chandran, Kartik

PY - 2011/5/6

Y1 - 2011/5/6

N2 - Ebola virus (EboV) and Marburg virus (MarV) (filoviruses) are the causative agents of severe hemorrhagic fever. Infection begins with uptake of particles into cellular endosomes, where the viral envelope glycoprotein (GP) catalyzes fusion between the viral and host cell membranes. This fusion event is thought to involve conformational rearrangements of the transmembrane subunit (GP2) of the envelope spike that ultimately result in formation of a six-helix bundle by the N- and C-terminal heptad repeat (NHR and CHR, respectively) regions of GP2. Infection by other viruses employing similar viral entry mechanisms (such as HIV-1 and severe acute respiratory syndrome coronavirus) can be inhibited with synthetic peptides corresponding to the native CHR sequence ("C- peptides"). However, previously reported EboV C-peptides have shown weak or insignificant antiviral activity. To determine whether the activity of a C-peptide could be improved by increasing its intracellular concentration, we prepared an EboV C-peptide conjugated to the arginine-rich sequence from HIV-1 Tat, which is known to accumulate in endosomes. We found that this peptide specifically inhibited viral entry mediated by filovirus GP proteins and infection by authentic filoviruses. We determined that antiviral activity was dependent on both the Tat sequence and the native EboV CHR sequence. Mechanistic studies suggested that the peptide acts by blocking a membrane fusion intermediate.

AB - Ebola virus (EboV) and Marburg virus (MarV) (filoviruses) are the causative agents of severe hemorrhagic fever. Infection begins with uptake of particles into cellular endosomes, where the viral envelope glycoprotein (GP) catalyzes fusion between the viral and host cell membranes. This fusion event is thought to involve conformational rearrangements of the transmembrane subunit (GP2) of the envelope spike that ultimately result in formation of a six-helix bundle by the N- and C-terminal heptad repeat (NHR and CHR, respectively) regions of GP2. Infection by other viruses employing similar viral entry mechanisms (such as HIV-1 and severe acute respiratory syndrome coronavirus) can be inhibited with synthetic peptides corresponding to the native CHR sequence ("C- peptides"). However, previously reported EboV C-peptides have shown weak or insignificant antiviral activity. To determine whether the activity of a C-peptide could be improved by increasing its intracellular concentration, we prepared an EboV C-peptide conjugated to the arginine-rich sequence from HIV-1 Tat, which is known to accumulate in endosomes. We found that this peptide specifically inhibited viral entry mediated by filovirus GP proteins and infection by authentic filoviruses. We determined that antiviral activity was dependent on both the Tat sequence and the native EboV CHR sequence. Mechanistic studies suggested that the peptide acts by blocking a membrane fusion intermediate.

UR - http://www.scopus.com/inward/record.url?scp=79955542545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955542545&partnerID=8YFLogxK

U2 - 10.1074/jbc.M110.207084

DO - 10.1074/jbc.M110.207084

M3 - Article

VL - 286

SP - 15854

EP - 15861

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 18

ER -